Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7950188 | 0.85 | NCF1 (0.39) | GAARAD52KMT2ANCF1CYP1A2 | |
| SCHEMBL19783894 | 0.85 | KDM4E (0.35) | KDM4EALDH1A1 | |
| SCHEMBL2012671 | 0.79 | VNN1 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL17734308 | 0.77 | KDM4E (0.32) | GAAKDM4EALDH1A1 | |
| SCHEMBL12535978 | 0.77 | KDM4E (0.38) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL290856 | 0.77 | — | — | |
| SCHEMBL24091187 | 0.77 | GRIN2D (0.39) | PTPN11 | |
| SCHEMBL9851667 | 0.76 | DRD4 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL19321830 | 0.76 | KDM4E (0.37) | GAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL23508955 | 0.76 | PTPN11 (0.35) | GAARAD52KMT2ANCF1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11001561-B2 | Pyrimidinone derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-20200317622-A1 | PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS | EMD SERONO RESEARCH AND DEVELOPMENT, INC. | 2020-10-08 | — | — | US | disclosed |
| WO-2020081848-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| CN-1863784-B | 2-naphthylimino-1,3-thiazine derivative | SHIONOGI & CO | 2010-11-17 | — | — | CN | disclosed |
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-7482339-B2 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| CN-1863784-A | 2-naphthylimino-1,3-thiazine derivative | SHIONOGI & CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001561-B2 | Pyrimidinone derivatives as SHP2 antagonists | PTPN5, PTPN1, PTPN2 | GAA 1852/4885RAD52 3169/4885KMT2A 926/4885 |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | NPM1, OXTR, CYP2S1 | GAA 4311/4885RAD52 3868/4885KMT2A 3233/4885 |
| US-20090076015-A1 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring | KCNH1, SCN1A, SCN10A | GAA 3292/4885RAD52 4530/4885KMT2A 500/4885 |
| US-20200317622-A1 | PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS | PTPN5, PTPN1, PTPN2 | GAA 1852/4885RAD52 3169/4885KMT2A 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.